Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China
|
MSCI China Small-Cap
|
Hang Seng Index
|
Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
    • China ESG Focus
  • Fast News
  • Expert Corner
  • Audio/Video
  • IPO
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
    • China ESG Focus
  • Fast News
  • Expert Corner
  • Audio/Video
  • IPO
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

biotech

Sino Biopharma’s LaNova bet pays off

Sino Biopharma’s M&A move pays off with big licensing deal

The Chinese drugmaker stands to gain more than $7 billion from a partnership with Germany’s Boehringer if its therapies can deliver clinical and commercial results Key Takeaways: Most of the…
November 12, 2026
1177.HK

Legend Biotech shares tumble as Carvykti outlook overshadows profit

Cancer treatment developer Legend Biotech Corp. (LEGN.US) reported on Tuesday that its third-quarter revenue rose 32% year-on-year to $359.5 million, while its net income reached $51.7 million, reversing a $39.6…
November 11, 2026
LEGN.US
Akeso’s overseas drug promise fails to slow share decline

Akeso’s overseas drug promise fails to slow share decline

The Chinese drugmaker has been under pressure on equity markets since revealing plans for a share placement, overriding positive news for its key cancer therapy Key takeaways: Akeso’s shares have…
October 29, 2026
9926.HK
AcroBiosystems renewed Hong Kong listing bid

AcroBiosystems leans on overseas sales in renewed Hong Kong listing bid

The company leads the field for recombinant proteins among its domestic peers, but overseas companies dominate the international market Key Takeaways: AcroBiosystems has applied to list in Hong Kong, reporting…
October 22, 2026
301080.SHE
 Hengrui Pharma’s cancer drug fuzuloparib is being reviewed by EU regulators

Hengrui makes headway with novel drugs but investors bide their time

A cancer drug developed by the Chinese firm has entered the European regulatory process and Novo Nordisk has bought rights to a potential weight-loss therapy Key Takeaways: Hengrui Pharma’s cancer…
October 15, 2026
1276.HK
600276.SHG
Hansoh lost its regulatory approval

Hansoh’s overseas ambitions tested as EU stalls cancer drug sales

The Chinese firm has lost its regulatory approval to sell a lung cancer drug in Europe over a data-protection error, and must reset the clock on the launch process Key…
October 8, 2026
3692.HK
Cloudbreak Pharma shares halted amid probe into “IPO rigging”

Cloudbreak Pharma shares halted amid probe into ‘IPO rigging’

Just 14 months after its market debut, the drug developer is under investigation over regulatory concerns that its IPO demand was artificially inflated Key Takeaways: Cloudbreak’s IPO drew strong retail…
September 17, 2026
2592.HK
Load more

Recent Articles

Sino Biopharma’s LaNova bet pays off
November 12, 2026

Sino Biopharma’s M&A move pays off with big licensing deal

1177.HK
November 11, 2026

Legend Biotech shares tumble as Carvykti outlook overshadows profit

LEGN.US
October 29, 2026

Akeso’s overseas drug promise fails to slow share decline

9926.HK
October 22, 2026

AcroBiosystems leans on overseas sales in renewed Hong Kong listing bid

301080.SHE
October 15, 2026

Hengrui makes headway with novel drugs but investors bide their time

1276.HK
600276.SHG
October 8, 2026

Hansoh’s overseas ambitions tested as EU stalls cancer drug sales

3692.HK
September 17, 2026

Cloudbreak Pharma shares halted amid probe into ‘IPO rigging’

2592.HK

RELATED ARTICLES

  1. Alphamab AI deal
    August 13, 2026
    Alphamab seals $2.2 billion licensing deal with AI biotech
    9966.HK
  2. June 4, 2026
    Innovent’s $10.5 billion deal marks new model for China drugmakers
    1801.HK
  3. May 20, 2026
    The global leap: Chinese biopharma, athletic brands dip toes in global waters
    1530.HK
    1368.HK
  4. October 15, 2026
    Hengrui makes headway with novel drugs but investors bide their time
    1276.HK
    600276.SHG
  5. October 8, 2026
    Hansoh’s overseas ambitions tested as EU stalls cancer drug sales
    3692.HK
  6. July 9, 2026
    Drug setback leaves Ascletis with an all-in bet on weight loss
    1672.HK
  7. July 16, 2026
    Insilico revenue soars above $100 million on AI drug partnerships
    3696.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2026 Bamboo Works. All rights reserved.